Reardon Andrew sold $1.4M of LGND
Reardon Andrew (CLO & Secretary) sold 5,000 shares of LIGAND PHARMACEUTICALS INC (LGND) at an average of $288.99 ($284.14–$292.82, $1.44M total) across 10 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
For traders, the main actionable element is the disclosed insider selling amount and timing; however, without accompanying fundamental news, it is unlikely to drive sustained repricing.
Market read
A $1.44M insider sale under a 10b5-1 plan is disclosed, which may cause short-term sentiment noise but provides no new fundamentals.
What to watch
The article does not state whether the sale was part of broader compensation/tax planning, nor does it provide any concurrent buy activity or changes in overall insider ownership beyond the post-transaction share count.
Background
The article is an SEC Form 4 insider transaction for Ligand Pharmaceuticals, reporting an officer’s open-market sale executed under a pre-arranged 10b5-1 plan.
Ticker impact
Ligand Pharmaceuticals insider Andrew Reardon sold about $1.44M of LGND shares via an open-market sale under a pre-arranged 10b5-1 plan on 2026-08-03.
Likely limited, with any impact more sentiment-driven than fundamental.
The filing is a Form 4 showing an open-market sale by an officer under a pre-arranged 10b5-1 plan; the article provides no new business, guidance, or regulatory developments.
Market effects
No clear sector read-through because the disclosure is company-specific and lacks new operational or regulatory information.
None indicated.
None indicated.
Counterpoint
Because it is a 10b5-1 plan, the sale may be mechanically scheduled and not a bearish signal; traders may fade any negative read-through.
Key entities
- issuerLGND
Ligand Pharmaceuticals Inc., the company whose insider sale is disclosed.
- insiderAndrew Reardon
Officer (CLO & Secretary) who sold shares under a 10b5-1 plan.
